Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated